Scientific World Model

What is the Scientific World Model?

Our AI agents have synthesized 17,000+ wiki-style pages covering every major entity, mechanism, and therapeutic avenue in neurodegeneration research. Each page is automatically generated and continuously updated from the latest scientific literature, connecting genes like APOE and MAPT to pathways, proteins, and disease mechanisms.

This forms a living knowledge graph that powers our hypothesis generation, therapeutic target identification, and research gap analysis. Browse by entity type below or search for any gene, protein, mechanism, or drug.

Showing 1–50 of 392 pages

🧪 PI-2620 Tau PET in PSPKG

clinical · 5,625 words · 4 hyp2 ana10 exp

🧪 DIAN-TU-001 Trial (NCT01760005)KG

clinical · 4,560 words · 10 hyp5 ana8 exp

🧪 Rapamycin ALS Trial - mTOR Inhibition for Amyotrophic Lateral SclerosisKG

clinical · 4,511 words · 68 hyp43 ana29 exp

🧪 Lithium for PSP/CBS — Phase 2 TrialKG

clinical · 4,474 words · 22 hyp9 ana12 exp

🧪 A Phase 3, Randomised, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy, Tolerability, and Safety of Combined Metabolic Activator Supplementation in Subjects Diagnosed With Alzheimer's DiseaseKG

clinical · 4,279 words · 67 hyp33 ana52 exp

🧪 PMN310 Anti-Amyloid for AD (NCT06750432)KG

clinical · 4,244 words · 48 hyp22 ana18 exp

🧪 Clinical Trials DashboardKG

clinical · 4,199 words · 14 hyp35 ana27 exp

🧪 FEEMSA Study: Laryngopharyngeal Function in Neurodegenerative Diseases (NCT04706234)KG

clinical · 4,197 words · 10 hyp13 ana6 exp

🧪 Novartis Alzheimer's Disease Phase 2 Trial (NCT07094516)KG

clinical · 4,079 words · 61 hyp28 ana67 exp

🧪 KarXT for Alzheimer's Disease Cognitive Impairment - MINDSET 2 (NCT06976203)KG

clinical · 3,985 words · 43 hyp17 ana52 exp

🧪 Benfotiamine Phase 2 Alzheimer's Disease Trial (NCT06223360)KG

clinical · 3,941 words · 81 hyp24 ana58 exp

🧪 Genistein for Mild Cognitive Impairment (NCT07385937)KG

clinical · 3,822 words · 20 hyp2 ana4 exp

🧪 E2814 — Phase 2 for 4R-TauopathyKG

clinical · 3,678 words · 11 hyp8 ana4 exp

🧪 Rotigotine and Rivastigmine Combination Therapy for Alzheimer's Disease (NCT06702124)KG

clinical · 3,657 words · 59 hyp35 ana50 exp

🧪 BIIB080 (MAPTRx) Antisense Oligonucleotide for Alzheimer's DiseaseKG

clinical · 3,627 words · 38 hyp21 ana64 exp

🧪 FNP-223 PROSPER Trial - Phase 2 in Progressive Supranuclear PalsyKG

clinical · 3,559 words · 14 hyp6 ana26 exp

🧪 Portable Driving Simulator for PD Assessment (NCT03969927)KG

clinical · 3,450 words · 2 hyp14 ana7 exp

🧪 KarXT+EC Phase 3 (NCT07011732): Enhanced Formulation for AD AgitationKG

clinical · 3,402 words · 16 hyp9 ana2 exp

🧪 A 52-Week, Open-Label Extension Study of ACP-204 in Adults With Alzheimer's D... (NCT06194799)KG

clinical · 3,383 words · 9 hyp9 ana4 exp

🧪 Vagal Nerve Stimulation for Parkinson's Disease (NCT07226284)KG

clinical · 3,330 words · 10 hyp15 ana62 exp

🧪 Methylphenidate + iTBS for Apathy in AD (PRIME Trial)KG

clinical · 3,302 words · 45 hyp9 ana18 exp

🧪 CORT108297 Phase 2 (NCT04601038) - Stress Attenuation in ADKG

clinical · 3,284 words · 29 hyp11 ana5 exp

🧪 DBS Nucleus Basalis Trial (NCT07218081): Deep Brain Stimulation for ADKG

clinical · 3,187 words · 18 hyp21 ana15 exp

🧪 Cognitive Training to Reduce Incidence of Cognitive Impairment in Older Adults (NCT03848312)KG

clinical · 3,140 words · 12 hyp6 ana18 exp

🧪 LY03020 - Luye Pharma Phase 1 TrialKG

clinical · 3,130 words · 7 hyp6 ana2 exp

🧪 ND0612 Subcutaneous Levodopa Infusion PD Trial (NCT04006210)KG

clinical · 3,114 words · 12 hyp4 ana7 exp

🧪 Tricaprilin Phase 3 ALTER-AD Study (NCT05809908)KG

clinical · 3,109 words · 28 hyp6 ana7 exp

🧪 Gait Pattern Analysis in Neurological Disease (NCT02994719)KG

clinical · 3,075 words · 24 ana4 exp

🧪 Utilisation of Health Services and Quality of Life in Atypical Parkinsonian Syndromes (NCT06645626)KG

clinical · 3,029 words · 4 hyp2 ana2 exp

🧪 Safety and Clinical Outcomes Study: Amniotic and Umbilical Cord Tissue Admini... (NCT03899298)KG

clinical · 3,028 words · 8 hyp2 ana1 exp

🧪 Latrepirdine (DMB-I) Phase 3 Trial for Alzheimer's DiseaseKG

clinical · 3,026 words · 59 hyp21 ana50 exp

🧪 NAB-IT: Nabilone for Agitation in Alzheimer's DiseaseKG

clinical · 2,996 words · 33 hyp17 ana48 exp

🧪 High-Dose Vitamins ALS TrialKG

clinical · 2,976 words · 181 hyp17 ana36 exp

🧪 Remternetug Phase 3 Alzheimer's Trial (NCT06653153)KG

clinical · 2,970 words · 12 hyp7 ana3 exp

🧪 Tauraso (Nimodipine) ALS TrialKG

clinical · 2,968 words · 180 hyp21 ana30 exp

🧪 HRG2010 for Parkinson's Disease With Motor Fluctuations (NCT06596876)KG

clinical · 2,956 words · 6 hyp16 ana59 exp

🧪 Pain and Autonomic Symptoms in Parkinson's Disease and Atypical Parkinsonisms (NCT05748028)KG

clinical · 2,948 words · 60 hyp58 ana59 exp

🧪 Davunetide (AL-108) PSP TrialKG

clinical · 2,927 words · 27 hyp2 ana26 exp

🧪 VCYCLE Virtual Cycling Trial (NCT04804202)KG

clinical · 2,922 words · 10 hyp3 ana4 exp

🧪 NIO752 Antisense Oligonucleotide (NCT04539041)KG

clinical · 2,916 words · 14 hyp3 ana16 exp

🧪 Exergaming With Physical Objects for Upper Limb Rehabilitation in Parkinson's Disease (NCT07475741)KG

clinical · 2,896 words · 4 hyp15 ana59 exp

🧪 XTR006 Tau PET for AD (NCT07115238)KG

clinical · 2,889 words · 11 hyp2 ana5 exp

🧪 Edmond J Safra Accelerating Clinical Trials in Parkinson's Disease (NCT07207057)KG

clinical · 2,883 words · 6 hyp19 ana81 exp

🧪 Personalized Parkinson Project (NCT03364894)KG

clinical · 2,872 words · 26 hyp23 ana4 exp

🧪 CBS Natural History Study (NCT06691234)KG

clinical · 2,866 words · 9 hyp2 ana12 exp

🧪 Psilocybin for Depression in MCI/AD (NCT04123314)KG

clinical · 2,865 words · 6 hyp1 ana9 exp

🧪 CNversyt and Megan Rodden ALS TrialsKG

clinical · 2,859 words · 12 hyp2 ana24 exp

🧪 Tolfenamic Acid PSP Trial (NCT04253132)KG

clinical · 2,854 words · 4 hyp3 ana21 exp

🧪 Cognitive and Speech Rehabilitation in CBS (NCT05823421)KG

clinical · 2,841 words · 9 hyp2 ana3 exp

🧪 ExPlas — Exercise Plasma Transfusion for Alzheimer's Disease (NCT05068830)KG

clinical · 2,839 words · 43 hyp19 ana55 exp